Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

388 Reports from FirstWord

   
  • RCC: KOL Insight [2017]

    ...stage. KOLs now argue that the first-line treatment of advanced RCC is on the cusp of a second wave of change. At the forefront is a multitude of immunotherapy-based combination regimens that look set to ... Read More

  • Evidence Matters – Why Pharma Needs to Get Serious about Data

    ...from every quarter lengthens. Against this challenging backdrop, every decision made must be backed up by evidence. But exactly what evidence is required by whom, and how should it be prioritised, gathered, interpreted and leveraged ... Read More

  • What do Patients want from Pharma? The Real Patient-Centric Perspective

    ...The patient voice is becoming increasingly influential and patient groups are looking to pharma for practical and sustained support. But what services do patients want, how do they want them delivered, how do they see ... Read More

  • Type 2 Diabetes Mellitus [2016]: Bulletin #3

    ...from the Phase IIIb/IV EXSCEL study evaluating the effect of once-weekly Bydureon versus placebo in type-2 diabetics; the FDA’s boxed warning on risks of foot amputations for Johnson & Johnson’s canagliflozin (Invokana/Invokamet) based on data ... Read More

  • Medical Affairs Reputations (EU5) [Melanoma]

    ...things in the EU5 countries. Oncologists gave it the highest overall score and the highest performance and satisfaction ratings on most medical affairs services. Meanwhile, a rival team has done just the opposite, earning the ... Read More

  • Market Access Impact (US) [Haemophilia B]

    ...there’s room for brands to grow. To seize that opportunity, you need to understand the market barriers that are preventing doctors from prescribing your brand, and address the ones that are costing you market share. ... Read More

  • Market Access Impact (EU5) [Parkinson's Disease]

    ...surveyed to lose market share while the other half gain. Patient-related barriers are the main culprits, but understanding the unique combination of barriers and competitive dynamics your brand faces is critical if you want to ... Read More

  • Ulcerative Colitis [2016]: Bulletin #3

    ...the presentation of real-world analyses for Entyvio (vedolizumab) in UC; InDex Pharmaceuticals announcing that it has enrolled the first patient in the Phase IIb CONDUCT trial for Kappaproct (cobitolimod); as well as Amgen announcing the ... Read More

  • Colorectal Cancer [2016]: Bulletin #3

    ...II, CheckMate-142 trial evaluating Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); Roche announcing data ... Read More

  • NPS+ (US) [Growth Hormone Deficiency]

    ...options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ ... Read More

  • Market Access Impact (US) [Asthma/COPD]

    ...roughly 55% of doctors can’t prescribe certain brands because they’re either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of ... Read More

  • Market Access Impact (EU5) [Asthma/COPD]

    ...to a handful of brands, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors aren’t prescribing them because they don’t know they exist. Market Access Impact: Asthma/COPD (EU5) shows ... Read More

  • Medical Affairs Reputations (EU5) [Cancer Pain]

    ...turned in a disappointing performance in the past 6 months. Their ratings on individual services barely crept above neutral, and they’re failing to deliver the information doctors need. Nevertheless, doctors are open to more frequent ... Read More

  • Medical Affairs Reputations (US) [Melanoma]

    ...only did they earn the highest overall scores, the oncologists we surveyed gave them the highest performance and satisfaction ratings on almost every medical affairs service we asked about. This report reveals how your team ... Read More

  • Market Access Impact (EU5) [Haemophilia B]

    ...are willing to consider them, so there’s room for brands to grow. To seize that opportunity, you need to understand the market barriers that are preventing doctors from prescribing your brand, and address the ones ... Read More

  • Market Access Impact (US) [Parkinson's Disease]

    ...the 11 Parkinson’s disease treatments we asked them about are losing market share because of barriers. High cost and market access problems are the main culprits, but understanding the unique combination of barriers and competitive ... Read More

  • SLE: KOL Insight [2017]

    ...Rituxan/MabThera (rituximab), now experiencing biosimilar competition in Europe, is also used off-label. Despite these advances significant unmet need remains in the treatment of SLE. Novel products are on the horizon, including anifrolumab (BMZ/AstraZeneca), forigerimod (ImmunPharma) ... Read More

  • Rheumatoid Arthritis [2017]: Bulletin #1

    ...issuance of a complete response letter, in April 2017, regarding Elli Lilly’s Janus-kinase inhibitor Olumiant (baricitinib), requesting additional dosing and safety data; the European approval, in March 2017, of Pfizer’s Janus-kinase inhibitor, Xeljanz (tofacitinib), following ... Read More

  • NPS+ (EU5) [Growth Hormone Deficiency]

    ...some brands are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? ... Read More

  • Multiple Myeloma: KOL Insight [2017]

    ...current range of treatment options – such as Celgene’s Revlimid and Takeda’s Velcade, and combination regimens of various therapies – are well established, unmet needs persist in the market for safe and effective drugs that ... Read More

  • Medical Affairs Reputations (US) [Cancer Pain]

    ...a lacklustre performance in the past 6 months. Their ratings on individual services barely crept into positive territory, and even though they’re contacting doctors a little too often, they’re failing to deliver the information doctors ... Read More

  • CAR-T Disease Outlook [2017]

    ...leukaemia (ALL) and non-Hodgkin lymphoma (NHL) with high unmet needs. How will the impressive efficacy and safety of these therapies pan out in the long-term? Key opinion leaders (KOLs) explore the clinical challenges and opportunities ... Read More

  • Hepatitis C [2016]: Bulletin #3

    ...results of its triple combination JNJ-4178 (simeprevir/odalasvir/AL-335) in an ongoing Phase II study; AbbVie announcing positive data from two Phase III studies, ENDURANCE-3 and EXPEDITION-1, with its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Merck & Co. ... Read More

  • Melanoma [2016]: Bulletin #2

    ...Application (NDA) in the US seeking approval of binimetinib for the treatment of neuroblastoma RAS viral oncogene homologue (NRAS) mutation-positive melanoma; NewLink Genetics reporting positive interim results from a Phase II study evaluating its IDO ... Read More

  • Multiple Sclerosis [2016]: Bulletin #2

    ...approval of Ocrevus (ocrelizumab, Roche/Biogen) as a therapy for relapsing and primary progressive forms of MS; AB Science announcing that its oral tyrosine kinase inhibitor, masitinib, has passed the two-year non-futility test in a Phase ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook